Abstract 34P
Background
Resilience to stress is a central phenotype underlying cancer cell biology. Cancer resilience empowers cell growth and survival in the face of harsh microenvironments, cytotoxic therapies, and loss of normal cellular regulatory processes. By understanding the mechanisms underlying cancer cell resilience, we may develop therapies which constrain tumors generally or synergize with existing drugs. Here, we sought to identify yet-unknown mechanisms by which cancer cells orchestrate resilience.
Methods
Using genome-scale CRISPR-Cas9 screening data from over 700 unique cancer cell lines (DepMap project), we developed a guilt-by-association “coessentiality” approach to identify genes involved cellular stress response signaling. We then used a combination of molecular biology, evolutionary biology, and computational biology approaches to validate predictions.
Results
Using an unbiased functional genomic approach and subsequent molecular validation, we identified HAPSTR1 (formerly: C16orf72) as a gene which becomes particularly important to cancer cells under stress conditions (e.g., DNA damage, protein aggregation, nutrient starvation). HAPSTR1, despite conservation through worms, yeast, and plants, had no known function. We found that HAPSTR1 encodes a dimeric protein which enables nuclear localization of HUWE1, an otherwise cytoplasmic ubiquitin ligase. Additionally, we show that mammals have a second HAPSTR gene, HAPSTR2 (formerly: RP11-364B14.3), which formed via an atypical evolutionary mechanism and functions to buffer the HAPSTR-HUWE1 pathway in specific cancer subsets.
Conclusions
Altogether, we present a new gene family and biochemical pathway leveraged by cancer cells to empower resilience. Disruption of this pathway broadly impairs stress response regulation and may thus be relevant to understanding and targeting resilience in human tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Institutes of Health (NIH-USA).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
21P - DNAJC1 inhibit the ferroptosis of glioma cells through stabilizing GPX4 by competing with TRIM21
Presenter: Min Chao
Session: Poster session 07
Resources:
Abstract
22P - Pre-clinical development of CVGBM: A therapeutic mRNA-based multiepitope vaccine for glioblastoma
Presenter: Ronja Mülfarth
Session: Poster session 07
23P - Germline testing in a selected cohort of non-small cell lung cancer (NSCLC) patients: Final results from the INHERITY LC study
Presenter: Maria Zurera Berjaga
Session: Poster session 07
24P - Assessment of an AI algorithm to classify germline variants in the ATM cancer predisposition gene
Presenter: Nooshin Bayat
Session: Poster session 07
25P - NGS-based identification of novel hereditary breast/ovarian cancer genes in patients with clinical features of genetic predisposition
Presenter: Ekaterina Kuligina
Session: Poster session 07
26P - Multi-feature cell free DNA analysis and ensemble machine learning for early detection of cancer
Presenter: Seongmun Jeong
Session: Poster session 07
27P - Molecular insights on cutaneous melanoma hyperpigmentation and therapy resistance
Presenter: Elena Andreucci
Session: Poster session 07
28P - Targeting YAP1 as a biomarker of resistance and therapeutic strategy in melanoma immunotherapy
Presenter: Szonja Kovács
Session: Poster session 07
29P - Considering intra-patient response variability in clinical trials: Implications for treatment efficacy and survival
Presenter: Caryn Geady
Session: Poster session 07
Resources:
Abstract
30P - CDK4/6 inhibitors dephosphorylate RNF26 to stabilize TSC1 and increase the sensitivity of ccRCC to mTOR inhibitors
Presenter: Yang Zheng
Session: Poster session 07